Skip to content
The Policy VaultThe Policy Vault

ZenzediCareFirst (Caremark)

Moderate to severe binge-eating disorder (BED)

Preferred products

  • Adzenys ER
  • Adzenys XR-ODT
  • Adderall XR
  • Evekeo ODT
  • methylphenidate chewable tablet
  • methylphenidate immediate release
  • Aptensio XR
  • Concerta
  • Cotempla XR-ODT
  • methylphenidate CD
  • Methylphenidate Osmotic Extended-Release
  • Relexxii
  • Ritalin LA
  • Focalin
  • Focalin XR

Initial criteria

  • For ADHD or ADD: The patient has a diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD).
  • The diagnosis has been appropriately documented (e.g., evaluated by a complete clinical assessment, using DSM-5, standardized rating scales, interviews/questionnaires).
  • If the patient is age ≤ 5 years, the patient continues to have ADHD/ADD symptoms despite participating in evidence-based behavioral therapy (e.g., parent training in behavior management (PTBM), behavioral classroom interventions).
  • For Narcolepsy: The patient has a diagnosis of narcolepsy, and the diagnosis has been confirmed by a sleep study.
  • The requested drug is NOT amphetamine extended-release (Adzenys ER, Adzenys XR-ODT), amphetamine-dextroamphetamine extended-release (Adderall XR), amphetamine sulfate orally disintegrating tablet (Evekeo ODT), methylphenidate chewable tablet, methylphenidate immediate release, methylphenidate extended-release (Aptensio XR, Concerta, Cotempla XR-ODT, methylphenidate CD, Methylphenidate Osmotic Extended-Release, Relexxii, Ritalin LA), dexmethylphenidate (Focalin), or dexmethylphenidate extended-release (Focalin XR).
  • The requested drug is being prescribed by, or in consultation with, a sleep specialist.

Reauthorization criteria

  • For ADHD or ADD: The patient achieved or maintained improvement in their signs and symptoms of ADHD/ADD from baseline.
  • The patient’s need for continued therapy has been assessed within the previous year.
  • For Narcolepsy: The patient has achieved or maintained improvement in daytime sleepiness with narcolepsy from baseline.
  • The request is NOT for amphetamine extended-release (Adzenys ER, Adzenys XR-ODT), amphetamine-dextroamphetamine extended-release (Adderall XR), amphetamine sulfate orally disintegrating tablet (Evekeo ODT), methylphenidate chewable tablet, methylphenidate immediate release, methylphenidate extended-release (Aptensio XR, Concerta, Cotempla XR-ODT, methylphenidate CD, Methylphenidate Osmotic Extended-Release, Relexxii, Ritalin LA), dexmethylphenidate (Focalin), or dexmethylphenidate extended-release (Focalin XR).